- The University of Chicago Medicine recruited 125 people with Covid-19
- two Phase 3 clinical trials
- 113 had severe disease
- All the patients been treated with daily infusions of remdesivir
- "The best news is that most of our patients have already been discharged, which is great. We've only had two patients perish," said Kathleen Mullane, the University of Chicago infectious disease specialist overseeing the remdesivir studies for the hospital.
Just if you ask yourself what the rally in S&P Globex is all about....
